Skip to content
Erudio Health
menu
Clinical trial · no report yet · Phase 3

STABLE-MATES

JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

  • NCT02468024 ↗
  • Recruiting
  • University of Texas Southwestern Medical Center
  • Standard

We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Preliminary discovery

Commentary in our index that names this trial so far

Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.

ChannelFound
X threads12
YouTube1

The trial

ClinicalTrials.gov
Official title
JoLT-Ca A Randomized Phase III Study of Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) in High Risk Patients With Stage I Non-Small Cell Lung Cancer (NSCLC), The STABLE-MATES Trial
Phase
Phase 3
Status
Recruiting
Conditions
Non-Small Cell Lung Cancer
Interventions
Lung Surgery; Radiation therapy
Arms
  • Arm 1 lung surgery · Active comparator
  • Arm 2 radiation therapy · Experimental
Enrollment
272 (estimated)
Primary outcomes
  • overall survival
Sponsor
University of Texas Southwestern Medical Center
Start
Jul 2015
Primary completion
Dec 2028 (estimated)
Results posted
No
Registry record
NCT02468024 · updated Apr 16, 2026

Publications

linked from the registry
  • Elbanna M, Shiue K, Edwards D, Cerra-Franco A, Agrawal N, Hinton J, Mereniuk T, Huang C, Ryan JL, Smith J, Aaron VD, Burney H, Zang Y, Holmes J, Langer M, Zellars R, Lautenschlaeger T. Impact of Lung Parenchymal-Only Failure on Overall Survival in Early-Stage Lung Cancer Patients Treated With Stereotactic Ablative Radiotherapy. Clin Lung Cancer. 2021 May;22(3):e342-e359. doi: 10.1016/j.cllc.2020.05.024. Epub 2020 Jun 2. PubMed 32736936